JECM:新型双重AMPK激活/mTOR抑制剂可抑制甲状腺癌细胞生长

2015-03-31 沐晴 译 MedSci原创

活化的5—磷酸腺苷蛋白激酶(AMPK)是细胞内调节能量稳态的关键因子,可通过抑制mTOR/p70S6K信号系统抑制肿瘤细胞生长。在体和离体实验研究均证明AMPK激活剂,如二甲双胍和AICAR,可以抑制甲状腺癌细胞的生长。OSU-53是一种新型的AMPK激动剂,以往有研究证明,它在离体和在体实验中都有抗进展性乳腺癌癌细胞的作用。近期,有研究就证明OSU-53也可以抑制甲状腺癌细胞的生长。研究者在实验

活化的5—磷酸腺苷蛋白激酶(AMPK)是细胞内调节能量稳态的关键因子,可通过抑制mTOR/p70S6K信号系统抑制肿瘤细胞生长。在体和离体实验研究均证明AMPK激活剂,如二甲双胍和AICAR,可以抑制甲状腺癌细胞的生长。OSU-53是一种新型的AMPK激动剂,以往有研究证明,它在离体和在体实验中都有抗进展性乳腺癌癌细胞的作用。

近期,有研究就证明OSU-53也可以抑制甲状腺癌细胞的生长。研究者在实验中评估了,OSU-53对甲状腺癌细胞生长、致癌信号系统、凋亡、自噬的影响,及基因敲出AMPK后,OSU-53对甲状腺癌细胞的治疗作用。

研究结果表明:在离体实验中,通过检测AMPK或诱导AMPK的活性,发现OSU-53可以抑制7种甲状腺癌细胞的生长,激活RAS或BRAF突变的细胞系,与抑癌基因PTEN缺乏和RET/PTC1突变的细胞系相比,对于OSU-53药物治疗更敏感,并且证明,过度激活AMPK活性,可以抑制mTOR信号系统及诱导细胞自噬。在选择性的基因敲出AMPK后,并没有观察到OSU-53的抑癌作用。因此,研究者认为,通过OSU-53直接抑制mTOR信号系统,并不能抑制甲状腺癌细胞的生长。实验还发现,激活RAS或BRAF基因突变,可以提高细胞自噬水平。

最后,研究者得出结论,OSU-53是一个双重的AMPK激活/ mTOR抑制剂,可以有效的抑制多种甲状腺癌细胞的生长,而且,在甲状腺癌细胞中RAS或BRAF基因突变被激活后,OSU-53抑制癌细胞生长的作用最强。

原始出处:

Plews RL, Mohd Yusof A, Wang C, Saji M, Zhang X, Chen CS, Ringel MD, Phay JE.A Novel Dual AMPK Activator/mTOR Inhibitor Inhibits Thyroid Cancer Cell Growth.J Clin Endocrinol Metab. 2015 Feb 24:jc20141777. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851235, encodeId=49331851235f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 04 13:01:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24694, encodeId=deb92469417, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252023, encodeId=4af9125202337, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489886, encodeId=95f91489886fe, content=<a href='/topic/show?id=df661233631' target=_blank style='color:#2F92EE;'>#mTOR抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12336, encryptionId=df661233631, topicName=mTOR抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f708628038, createdName=yankaienglish, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568988, encodeId=d4e315689883c, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
    2016-02-04 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851235, encodeId=49331851235f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 04 13:01:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24694, encodeId=deb92469417, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252023, encodeId=4af9125202337, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489886, encodeId=95f91489886fe, content=<a href='/topic/show?id=df661233631' target=_blank style='color:#2F92EE;'>#mTOR抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12336, encryptionId=df661233631, topicName=mTOR抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f708628038, createdName=yankaienglish, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568988, encodeId=d4e315689883c, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
    2015-05-24 ljjj1053

    不错,学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851235, encodeId=49331851235f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 04 13:01:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24694, encodeId=deb92469417, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252023, encodeId=4af9125202337, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489886, encodeId=95f91489886fe, content=<a href='/topic/show?id=df661233631' target=_blank style='color:#2F92EE;'>#mTOR抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12336, encryptionId=df661233631, topicName=mTOR抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f708628038, createdName=yankaienglish, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568988, encodeId=d4e315689883c, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
    2015-04-02 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851235, encodeId=49331851235f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 04 13:01:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24694, encodeId=deb92469417, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252023, encodeId=4af9125202337, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489886, encodeId=95f91489886fe, content=<a href='/topic/show?id=df661233631' target=_blank style='color:#2F92EE;'>#mTOR抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12336, encryptionId=df661233631, topicName=mTOR抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f708628038, createdName=yankaienglish, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568988, encodeId=d4e315689883c, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1851235, encodeId=49331851235f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 04 13:01:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24694, encodeId=deb92469417, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252023, encodeId=4af9125202337, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489886, encodeId=95f91489886fe, content=<a href='/topic/show?id=df661233631' target=_blank style='color:#2F92EE;'>#mTOR抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12336, encryptionId=df661233631, topicName=mTOR抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f708628038, createdName=yankaienglish, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568988, encodeId=d4e315689883c, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Thu Apr 02 04:01:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]

相关资讯

NEJM:Lenvatinib有望用于放射性碘难治性甲状腺癌治疗

Lenvatinib是一种多受体酪氨酸激酶(RTK)抑制剂,能够选择性抑制血管内皮生长因子(VEGF)受体、成纤维细胞生长因子受体(FGF)、血小板源性生长因子受体等激酶的活性。欧洲药品管理局(EMA)已于2014年7月授予实验性抗癌药物lenvatinib(E7080)加速审批资格,该药开发用于放射性碘难治性分化型甲状腺癌(RR-DTC)的治疗。NEJM杂志于2015年2月12日在线发表了一项关

卫材新型抗癌药Lenvima获日本批准,将成为甲状腺癌临床治疗新标准

卫材(Eisai)新型口服抗癌药Lenvima(lenvatinib)近日喜获日本批准用于不可切除性甲状腺癌的治疗。这也是该药继今年2月获美国批准之后,攻下的又一重要市场。此前,lenvatinib在美国、日本、欧盟均被授予孤儿药地位及优先审查资格。该药作为一种具有重大公共卫生利益的创新药物,将帮助解决甲状腺癌领域存在的严重未满足的医疗需求。 卫材表示,Lenvima将成为不可切除性甲状腺癌

NEJM:甲状腺癌的过度诊断尤其明显

随着检查手段的进步,许多癌症都能够在早期就被查出,这是为了挽救患者的生命,可有时候事实并非如此。一些对健康没有影响的低危癌症也被检出,不治疗让人感到不放心,可治疗却会对身体造成不必要的负担。 甲状腺癌的过度诊断 美国达特茅斯学院盖泽尔医学院的Welch教授发现,在1973~2002年间,被诊断为甲状腺癌的人增加了一倍,然而死于甲状腺癌的人数却没有什么变化。一般说来,如果癌症的早

ENDO 2015:乳腺癌确诊后,患甲状腺癌的风险增加

根据一项新的全国性大型数据库分析,乳腺癌幸存者患甲状腺癌的风险增加,尤其是在诊断出乳腺癌的五年内。该研究结果将在星期四举行的圣地亚哥内分泌学会第九十七届年会上。 纽约市哥伦比亚大学的外科助理教授,首席研究员Jennifer Hong Kuo医学博士说:“乳腺癌和甲状腺癌之间的练习认识提高了乳腺癌幸存者中警惕甲状腺癌的筛查。”  Kuo建议,乳腺癌幸存者的数量正在增加,鉴于她们比别人患

JAMA ONHS:不是歧视!不同人种及民族的甲状腺癌发病率存在差异

在过去30年里,甲状腺癌的发病率逐渐上升。人们发现,甲状腺癌在黑种人中的发病率似乎比白种人低。直到现在,甲状腺癌依然是亚洲及太平洋岛屿居民最常见的肿瘤之一。因此,研究人员希望通过调查研究,确定甲状腺癌的发病率在不同的人种和种族中的增长比例是不是相同的。该研究由美国宾夕法尼亚大学医学院耳鼻喉头颈外科的Angelina Magreni医师主持,研究结果发表在最新一期的JAMA Otolary

过度医疗苦果:韩国甲状腺癌早期诊断热

1、医学进步竟可以造成流行病? 流行病专家还有另外一项任务:识别和控制医疗界造成的流行病。韩国在过去20年里,这里甲状腺癌的发病率提高到了最初的15倍。全世界任何地方都没有哪种癌症能如此之快地增长。 我们受过的教育都是,为发病率的显著提高寻找生物学上的解释,或许是新的病原体,或许是环境暴露。然而在韩国,我们看到了不同的情况,这种流行病是因为诊断造成的。 2、韩国如何把甲状腺癌从罕见病变成常见